- Investing Ideas
- /
- Mexican Pharmaceuticals & Biotech Spotlight On Tobacco
Mexican Pharmaceuticals & Biotech Spotlight On Tobacco
UPDATED Apr 16, 2024
Get exposure to an age-old industry - tobacco.
148 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
LLY * | US$12,742.00 | 3.5% | 91.1% | US$672.6b | US$13,803.61 | PE129x | E27.1% | 0.7% | ||
NOVOB N | kr.2,099.19 | 0.8% | 40.8% | kr.3.9t | kr.2,178.46 | PE46.5x | E14.8% | 1.1% | ||
NVO N | kr.2,076.00 | 1.4% | 39.0% | kr.3.9t | kr.2,154.39 | PE46.5x | E14.8% | 1.1% | ||
JNJ * | US$2,471.50 | -1.1% | -14.9% | US$348.1b | US$2,953.91 | PE18.2x | E5.0% | 3.3% | ||
MRK * | US$2,175.79 | 4.7% | 5.1% | US$316.8b | US$2,380.50 | PE870x | E25.9% | 2.5% | ||
ABBV * | US$2,773.22 | -0.4% | -4.0% | US$287.8b | US$3,105.98 | PE60.3x | E22.8% | 3.8% | ||
TMO * | US$9,450.13 | 0.2% | -9.5% | US$211.7b | US$10,522.77 | PE34.8x | E10.6% | 0.3% | ||
AZN N | UK£1,146.32 | 3.1% | -14.1% | UK£168.4b | UK£1,375.86 | PE35.2x | E16.5% | 2.1% | ||
NVS N | CHF1,540.01 | -4.1% | n/a | CHF185.8b | CHF1,769.44 | PE23.8x | E9.5% | 3.9% | ||
NOVN N | CHF1,719.29 | 0% | n/a | CHF180.4b | CHF1,885.96 | PE26.2x | E10.1% | 3.5% | ||
ROG N | CHF4,025.87 | 0% | n/a | CHF177.3b | CHF5,118.42 | PE15.4x | E8.1% | 4.3% | ||
AZN1 N | UK£2,196.58 | 0% | -5.5% | UK£147.3b | UK£2,969.10 | PE31.2x | E17.5% | 2.4% | ||
DHR * | US$4,018.00 | -1.7% | -12.0% | US$178.0b | US$4,445.83 | PE42.2x | E11.3% | 0.4% | ||
PFE * | US$438.00 | 1.1% | -39.8% | US$145.5b | US$544.83 | PE67.5x | E22.1% | 6.6% | ||
AMGN * | US$4,449.50 | -2.2% | 0.09% | US$142.4b | US$5,059.40 | PE21.1x | E8.9% | 3.4% | ||
SAN1 N | €1,629.20 | 0% | -11.4% | €115.5b | €1,878.23 | PE12.7x | E5.7% | 3.9% | ||
SNY N | €795.00 | 0% | -20.7% | €108.4b | €977.23 | PE20.2x | E13.0% | 4.3% | ||
VRTX * | US$6,703.42 | 2.7% | 14.2% | US$101.9b | US$7,850.09 | PE28.1x | E11.4% | n/a | ||
BMY * | US$811.01 | -2.3% | -36.4% | US$97.8b | US$954.13 | PE12.1x | E8.2% | 5.0% | ||
REGN * | US$15,794.33 | 0% | 8.3% | US$96.6b | US$18,165.83 | PE24.3x | E10.9% | n/a | ||
CSL N | AU$3,635.42 | 0% | n/a | AU$145.0b | AU$4,103.81 | PE45.3x | E17.9% | 1.1% | ||
GILD * | US$1,129.86 | -0.1% | -25.2% | US$83.9b | US$1,452.25 | PE14.7x | E7.0% | 4.6% | ||
GSK1 N | UK£357.35 | 0% | n/a | UK£65.6b | UK£434.85 | PE13.6x | E9.4% | 3.5% | ||
GSK N | UK£655.00 | 0% | n/a | UK£65.0b | UK£818.56 | PE13.4x | E9.4% | 3.6% |